When the Network Becomes Destiny: How Korea's Daesan No.1 Clearance Reveals the Regulatory Paradox Pattern

On 20 August 2026 Korea's Fair Trade Commission conditionally approved the Daesan No.1 combination, the first structural realignment submitted by the country's petrochemical industry. HD Hyundai Chemical will absorb Lotte Daesan Petrochemical, and Lotte Chemical and HD Hyundai Oilbank will each hold 50% of the merged entity and control it jointly. The number of domestic suppliers in low-density polyethylene and ethylene-vinyl acetate falls from four to three. After the deal, the top three will hold 82% of LDPE and 95% of EVA by sales volume.

The remedies are entirely behavioural. For five years, domestic price movements in LDPE and EVA are benchmarked to export price movements. The companies must keep supplying every grade in production at the time of the combination when domestic buyers ask for it. Sharing of competitively sensitive information — prices, volumes, costs, inventory — is banned, as are dual appointments; staff returning to Lotte Chemical are excluded from LDPE and EVA work for one year. The commission added that the remedies can be extended if competition concerns persist after five years.

The pattern, and how this case differs from it. The Regulatory Paradox path describes a structural remedy whose execution takes so long that a new concentration forms inside the gap. This case is a variant rather than a textbook instance, and it is worth saying so: there is no divestiture here at all, so there is no execution gap. The gap has simply moved to the other end. Behavioural remedies govern conduct, and conduct can be regulated only for a stated period. Topology — who is connected to whom — carries no period. The remedy list is itself the evidence: you do not ban information flow between two parties unless a channel now exists between them. A firewall is built across a wire that has already been connected. The firewall expires in one year and in five. The wire does not.

Korea parallel. This matters more in Korea than the deal size suggests, because Korean market structure is unusually dense in exactly this respect — controlling families, cross-shareholdings and joint ventures mean that the number of legally separate competitors routinely overstates the number of economically independent ones. That is the whole premise behind tracking relational structure rather than reported financials: across the KOSPI and KOSDAQ names RaymondsIndex covers, the variable that most often turns out to have moved first is not a line item but a relationship. A supplier count is a headline number. An ownership graph is the thing that decides what that count means.

Three readings.

Warren (macro). Consolidation here is not a domestic story. Chinese capacity additions pushed the Korean industry into restructuring, and the same force is doing the same work in Europe — with the difference that nobody there is imposing conditions. LyondellBasell completed the sale of its European olefins and polyolefins assets on 1 May 2026, and the business relaunched as Velogy across Berre, Münchsmünster, Carrington and Tarragona. SABIC agreed in January 2026 to sell its European Petrochemicals business — Teesside, Geleen, Gelsenkirchen, Genk — to the same buyer, the Munich industrial group AEQUITA, at an enterprise value of $500 million, with completion still subject to regulatory approvals. Korea's concentration arrives as one reviewable transaction. Europe's arrives one carve-out at a time, from different sellers, and no single filing captures it.

Sam (investment). What can be measured gets priced, and a five-year window is highly measurable. The period after it is not, so it tends to be modelled as a continuation of the period before it. That is the mispricing worth naming: the remedy is a floor on competitive conduct, not a floor on market structure, and terminal value sits on the wrong side of the expiry date.

Phill (justice). Behavioural remedies transfer the burden of verification onto whoever is watching. A divestiture proves itself once. A price benchmark must be checked every year for five years, by someone with access. That asymmetry is not a technical detail — it decides who can tell whether the bargain held.

Academic frame. Gilo, Moshe and Spiegel (2006), "Partial cross ownership and tacit collusion," RAND Journal of Economics, show formally that partial ownership links between rivals can sustain tacit coordination that would not otherwise be sustainable — the channel matters independently of conduct. Motta, Polo and Vasconcelos (2007), "Merger remedies in the European Union: An overview," Antitrust Bulletin, survey why competition authorities have historically preferred structural to behavioural remedies, the monitoring burden of the latter being the recurring reason.

None of this says the KFTC decided wrongly. In an industry facing genuine overcapacity, forcing a divestiture can destroy the capacity it was meant to preserve, and the commission's grade-supply obligation is a real protection for buyers who would otherwise lose low-margin products first. The point is narrower and harder to argue with: two clocks are running, and only one of them has a number.

So when you build the case for a name in this sector, which years are you actually underwriting?

Based on public announcements. General structural observation, not investment advice.

#RaymondsRisk #RelationalRisk #CorporateGovernance #MergerRemedies #MarketStructure #Petrochemicals